ArticleCell communication and signaling : CCS2026
Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research advances on tumor-associated macrophages in pancreatic cancer.Biochemistry and biophysics reports · 2026Review
- The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited therapeutic options in part due to a dense stroma and the ability of the tumor cells to defy therapy by creating an immunosuppressive milieu. A histologic feature of PDAC is the abundance of immunosuppressive M2-polarized tumor-associated macrophages (TAMs) that favor cancer growth and metastases. Cancer cells communicate with immune cells of the tumor microenvironment (TME) by several mechanisms including exosomes to induce plasticity of the immune cells favoring pro-cancer instead of anti-cancer phenotypes. We examined a novel strategy to interrupt the cross-communication between cancer and immune cells by reprogramming the TME with a cholecystokinin-B receptor (CCK-BR) antagonist, proglumide.
methodsCross-communication was examined using 3-dimensional human PDAC spheroids that were either co-cultured with macrophages or treated with supernatant spent media from macrophages. RNA was extracted from the spheroids and subjected to RNA sequencing and Reverse Phase Protein Array (RPPA). RNA sequencing revealed that the most upregulated gene in the cancer cells after co-culture was ELANE, which codes for neutrophil elastase. Next, ELANE expression was down regulated by shRNA transfection in PDAC cells and the effect of the decreased expression was examined on the polarization of immune cells in vitro and in vivo in mice. Exosomes were also collected from PDAC spheroids for evaluation by RPPA.
resultsCo-culture of spheroids with macrophages increased cancer cell number and induced polarization of M0 macrophages to the M2-phenotype. Co-culture increased oncogenic pathways and genes by RPPA and RNA sequencing, respectively, and these changes were reversed with proglumide. ELANE knockdown in PDAC cells prevented the M2-polarization of macrophages in vitro and decreased tumor growth in vivo. Immunohistochemistry of ELANE knockdown tumors showed a shift in plasticity from M2-polarized TAMs to M1-polarized cells compared to wild-type tumors. Neutrophil elastase in cancer exosomes increased after co-culture and was abolished by treatment with proglumide.
conclusionELANE expression in PDAC cells regulates polarization of macrophages through the release of neutrophil-elastase rich exosomes. Proglumide therapy with CCK-B receptor antagonism is a novel method to interrupt cross-communication pathways between PDAC and immune cells in the TME and decrease cancer growth.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.